Lotti T, Hercogova J and Fabrizi G
Vitiligo is a skin disorder characterized by skin depigmentation caused by the loss of melanocytes. The causes of melanocyte loss are unclear, but a relevant number of observations lead researchers to ascribe cellular immunity as having an important role in vitiligo pathogenesis. Acting at the origin of the inflammatory phenomena, rebalancing the immune response with specific low dose SKA interleukins and antibodies and stimulating melanocytes to produce melanin via up-regulation of transmembrane receptors through SKA low dose basic-Fibroblast Growth Factor, represents the proposed Low Dose Medicine approach for Vitiligo treatment.
この記事をシェアする
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 